CIC
NBIX icon

Cornercap Investment Counsel’s Neurocrine Biosciences NBIX Stock Holding History

Cornercap Investment Counsel’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,859
Closed -$611K – 155
2025
Q2 		$611K Sell
4,859
-134
-3% -$15.4K 0.32% 136
2025
Q1 		$552K Sell
4,993
-64
-1% -$8.11K 0.29% 139
2024
Q4 		$690K Sell
5,057
-243
-5% -$30.1K 0.22% 138
2024
Q3 		$611K Sell
5,300
-3,594
-40% -$493K 0.18% 182
2024
Q2 		$1.22M Buy
+8,894
New +$1.22M 0.2% 140

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cornercap Investment Counsel's NBIX Position: Q3 2025 in Review

Cornercap Investment Counsel sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 4,859 shares — an estimated $611K sold.

Cornercap Investment Counsel first reported a position in NBIX in Q2 2024 and held it in 5 quarters. The position peaked at $1.22M in Q2 2024. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Cornercap Investment Counsel reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Cornercap Investment Counsel sold 4,859 Neurocrine Biosciences shares in Q3 2025, an estimated $611K.
  • Cornercap Investment Counsel first reported a position in Neurocrine Biosciences in Q2 2024 and held it in 5 quarters.
  • Cornercap Investment Counsel's Neurocrine Biosciences position peaked at $1.22M in Q2 2024.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Cornercap Investment Counsel's 13F filing for Q3 2025, filed 15 Oct 2025.